Stopping Cancer Early – The Best Possible Investment

Lung Cancer Biomarker Discovered by Canary Researchers Attracts New Interest From Academia and Industry

Team lead Dr. Samir Hanash discusses biomarker SFTPB’s journey from discovery to commercialization

Samir Hanash, M.D., Ph.D., is a member of the Canary Lung Cancer Team and led the team’s discovery of lung cancer biomarker SFTPB.

Searching for a needle in a haystack. That’s how Dr. Samir Hanash described the long, intensive process of finding a blood-based biomarker to detect lung cancer. So, when the Canary Lung Cancer Team, with Hanash at the helm, discovered a promising candidate called pro surfactant protein b (SFTPB), the potential impact was tremendous, especially since there has been only one other similar discovery to date.

Early validation studies of SFTPB have been so promising that multiple parties – among them The University of Texas MD Anderson Cancer Center and tech startup MagArray – have entered into negotiations with Canary Foundation to do further testing.

As part of a comprehensive lung cancer screening process, SFTPB has the potential to address shortcomings like false positives on CT scans as well as more accurately identify who should be screened and predict how frequently the person should be monitored.

Dr. Hanash recently discussed the discovery of biomarker SFTPB and its potential in a conversation with Canary Foundation that can be read below.

Canary Foundation: Can you explain the current state of lung cancer screening and why it is important to add biomarkers into the process?

Dr. Samir Hanash: The uptake of lung cancer screening with low dose CT has been quite modest in the U.S. and not at all in European countries. Blood-based biomarkers to determine the need for CT would represent a paradigm shift.

CF: When did your search for a lung blood biomarker begin?

SH: It began more than 15 years ago when I was at the University of Michigan.

CF: What makes it so difficult to pinpoint promising lung cancer biomarkers?

SH: Tremendous disease heterogeneity (diversity), limited availability of most informative samples for early detection, the need for in-depth high sensitivity methodology to find the needle in the haystack.

CF: At what point in the process did SFTPB emerge as a potential biomarker candidate?

SH: It emerged when we integrated data from mouse models of lung cancer with human data and lung cancer cell line data.

CF: What qualities does SFTPB have that led you to focus on it?

SH: We have subjected it to a multitude of blinded validation studies, and it came out significant for discriminating between lung cancer and controls.

CF: Validation studies of SFTPB have been very promising. What do these studies reveal in terms of the biomarker’s potential?

SH: That as part of a broader panel of biomarkers for lung cancer, it can be an effective tool for lung cancer screening.

CF: Now other groups are interested in further testing SFTPB and Canary Foundation has developed a licensing agreement to facilitate this. Why is additional testing necessary and what are the potential outcomes?

SH: There are many clinical indications related to lung cancer for which SFTPB may or may not be useful.

CF: If further studies of SFTPB continue to produce promising results, what are the next steps? How long could it be before SFTPB is used in lung cancer screening?

SH: That depends on performance in the most rigorous validation studies that meet FDA requirements.

Samir M. Hanash, M.D., Ph.D., is a professor in the Department of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center in Houston. We thank him for his insights.

Donor Spotlight: Franklin Whitecotton

Franklin Whitecotton is a resident of San Antonio, Texas and became a supporter of Canary Foundation in 2014. Read why he began supporting Canary in his own words below.

In Praise of Coal Mine Canaries

First, let me say I am honored to be asked to write a bit about Canary Foundation, the importance of their work, and the reasons I support them.

My mother and step-father both had cancer. In my step-father’s case, early detection might well have saved him a lot of misery and, in the end, his life. In my mother’s case it could have saved her from disfiguring surgery and chronic pain that was with her until the day she died.

I spent about twenty years of my life as a myotherapist involved in providing care for terminally ill patients. Some young, some old, all needing help in their day to day living, with their families and dealing with pain. I feel that almost all could have done without me if they had had an early detection and diagnosis made.

I have seen too many deaths from cancer related illnesses. Illnesses that could have been curtailed or avoided by early detection. That makes me incandescently angry! I found Canary when I came into some money from oil royalties and was looking for organizations that were really doing something to help others or promote learning.

That’s why I give to the Canary Foundation. Bio-markers, nanotechnology and their multidisciplinary approach to their research gives them a broader field to approach the problems from and more likelihood of finding successful techniques. I look forward to seeing their progress in the future and their ever increasing ability to find new paths for early detection.

Most Sincerely,

Franklin Whitecotton
Quiensabe Enterprises,LLC